Repository logo
 
Publication

Haploidentical α/β T-cell and B-cell Depleted Stem Cell Transplantation in Severe Mevalonate Kinase Deficiency

dc.contributor.authorFaraci, M
dc.contributor.authorGiardino, S
dc.contributor.authorPodestà, M
dc.contributor.authorPierri, F
dc.contributor.authorDell’Orso, G
dc.contributor.authorBeccaria, A
dc.contributor.authorFarela Neves, J
dc.contributor.authorVolpi, S
dc.contributor.authorGattorno, M
dc.date.accessioned2023-11-03T12:17:24Z
dc.date.available2023-11-03T12:17:24Z
dc.date.issued2021
dc.description.abstractObjective: Mevalonic aciduria represents the most severe form of mevalonate kinase deficiency (MKD). Patients with mevalonic aciduria have an incomplete response even to high doses of anti-cytokine drugs such as anakinra or canakinumab and stem cell transplantation (SCT) represents a possible therapy for this severe disease. Methods: We report the first two children affected by severe MKD who received haploidentical α/β T-cell and B-cell depleted SCT. Both patients received a treosulfan-based conditioning regimen and one received a second haploidentical-SCT for secondary rejection of the first. Results: Both patients obtained a stable full donor engraftment with a complete regression of clinical and biochemical inflammatory signs, without acute organ toxicity or acute and chronic GvHD. In both, the urinary excretion of mevalonic acid remained high post-transplant in the absence of any inflammatory signs. Conclusion: Haploidentical α/β T-cell and B-cell depleted SCT represents a potential curative strategy in patients affected by MKD. The persistence of urinary excretion of mevalonic acid after SCT, probably related to the ubiquitous expression of MVK enzyme, suggests that these patients should be carefully monitored after SCT to exclude MKD clinical recurrence. Prophylaxis with anakinra in the acute phase after transplant could represent a safe and effective approach. Further biological studies are required to clarify the pathophysiology of inflammatory attacks in MKD in order to better define the therapeutic role of SCT.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRheumatology (Oxford) . 2021 Oct 2;60(10):4850-4854pt_PT
dc.identifier.doi10.1093/rheumatology/keaa912pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4736
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.subjectAcute Diseasept_PT
dc.subjectB-Lymphocytes / transplantationpt_PT
dc.subjectInfant, Newbornpt_PT
dc.subjectMevalonate Kinase Deficiency / therapy*pt_PT
dc.subjectStem Cell Transplantation / methods*pt_PT
dc.subjectT-Lymphocytes / transplantationpt_PT
dc.subjectTransplantation, Haploidentical / methods*pt_PT
dc.subjectHDE PEDpt_PT
dc.titleHaploidentical α/β T-cell and B-cell Depleted Stem Cell Transplantation in Severe Mevalonate Kinase Deficiencypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage4854pt_PT
oaire.citation.issue10pt_PT
oaire.citation.startPage4850pt_PT
oaire.citation.titleRheumatologypt_PT
oaire.citation.volume60pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Rheumatology 2021_4850.pdf
Size:
158.12 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections